Eli Lilly and Co (LLY)
760.14
-11.41
(-1.48%)
USD |
NYSE |
May 10, 16:00
760.99
+0.85
(+0.11%)
After-Hours: 20:00
Eli Lilly Research and Development Expense (Annual): 9.313B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.313B |
| December 31, 2022 | 7.191B |
| December 31, 2021 | 6.931B |
| December 31, 2020 | 6.086B |
| December 31, 2019 | 5.595B |
| December 31, 2018 | 5.051B |
| December 31, 2017 | 5.096B |
| December 31, 2016 | 5.310B |
| December 31, 2015 | 4.796B |
| December 31, 2014 | 4.734B |
| December 31, 2013 | 5.531B |
| December 31, 2012 | 5.278B |
| December 31, 2011 | 5.021B |
| December 31, 2010 | 4.884B |
| December 31, 2009 | 4.326B |
| Date | Value |
|---|---|
| December 31, 2008 | 3.841B |
| December 31, 2007 | 3.487B |
| December 31, 2006 | 3.129B |
| December 31, 2005 | 3.026B |
| December 31, 2004 | 2.691B |
| December 31, 2003 | 2.350B |
| December 31, 2002 | 2.149B |
| December 31, 2001 | 2.235B |
| December 31, 2000 | 2.018B |
| December 31, 1999 | 1.784B |
| December 31, 1998 | 1.739B |
| December 31, 1997 | 1.370B |
| December 31, 1996 | 1.190B |
| December 31, 1995 | 1.042B |
| December 31, 1994 | 838.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
5.595B
Minimum
2019
9.313B
Maximum
2023
7.023B
Average
6.931B
Median
2021
Research and Development Expense (Annual) Benchmarks
| Amgen Inc | 4.784B |
| Biogen Inc | 2.462B |
| Johnson & Johnson | 15.08B |
| Vertex Pharmaceuticals Inc | 3.163B |
| Viking Therapeutics Inc | 63.81M |